Quadrivalent HPV vaccine in HIV-1-infected early adolescent girls and boys in Kenya: Month 7 and 12 post vaccine immunogenicity and correlation with immune status

• Published in: Vaccine 2018-11, Vol.36 (46), p.7025-7032
• Main Authors: Mugo, Nelly R., Eckert, Linda, Magaret, Amalia S., Cheng, Anqi, Mwaniki, Lawrence, Ngure, Kenneth, Celum, Connie, Baeten, Jared M., Galloway, Denise A., Wamalwa, Dalton, Wald, Anna
• Format: Article
• Language: English
• Subjects: Acquired immune deficiency syndrome; Adolescent; Adolescents; Age; AIDS; Antibodies, Viral - blood; Antiretroviral agents; Antiretroviral therapy; Blood; CD4 antigen; Cervical cancer; Child; Children; Children & youth; Complications; Drug therapy; Drug-Related Side Effects and Adverse Reactions - epidemiology; Drug-Related Side Effects and Adverse Reactions - pathology; Enrollments; Female; Girls; HIV; HIV Infections - complications; HIV-1; Human immunodeficiency virus; Human papillomavirus; Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 - administration & dosage; Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 - adverse effects; Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 - immunology; Humans; Immune response; Immune status; Immune system; Immunization; Immunization Schedule; Immunogenicity; Immunogenicity, Vaccine; Infections; Kenya; Laboratories; Male; Medical screening; Papillomavirus Infections - prevention & control; Plasma; Quadrivalent HPV vaccine; R&D; Research & development; Ribonucleic acid; RNA; Safety; Seroconversion; Sexually transmitted diseases; STD; Sub-Saharan Africa; Teenagers; United States; Vaccination; Vaccines; Womens health
• ISSN: 0264-410X; 1873-2518
• DOI: 10.1016/j.vaccine.2018.09.059

In sub-Saharan Africa, a generation of HIV-1-infected children is approaching the age of sexual debut and becoming at risk for HPV infection and its sequelae. We assessed safety and immunogenicity of the quadrivalent HPV (qHPV) vaccine in HIV-1-infected adolescents. In an open-label trial among Kenyan, HIV-1-infected adolescents aged 9–14 years, we administered the qHPV vaccine at 0, 2 and 6 months and measured antibody titers to HPV-16, 18, 6 and 11 at month 7 and 12 post-vaccination. Measures of immunogenic response from HIV-1-negative historical cohorts from Africa and HIV-1 positive adolescent cohorts from the USA were used for comparison. We enrolled 100 girls and 80 boys with a median age of 12 years and median baseline CD4 cell count of 684 (IQR 478, 935) cells/µL. One hundred and fifty four (86%) were receiving antiretroviral therapy for a median of 4.5 (IQR 2.3, 6.3) years; 110 (71%) had